ArticleTranslational cancer research2026
Inhibition of proliferation and metastasis of nasopharyngeal carcinoma by kaempferol via down-regulation of c-Jun.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nasopharyngeal carcinoma (NPC) is a highly aggressive malignancy of the head and neck, characterized by poor therapeutic outcomes. Kaempferol (Kae) has demonstrated significant potential in curbing tumor proliferation and metastasis, but its precise mechanism in NPC remains unclear. Given the critical role of the c-Jun/vascular endothelial growth factor (VEGF) axis in tumor progression, this study aims to investigate whether Kae suppresses NPC growth and metastasis through inhibition of this signaling pathway. Methods: Cell viability was assessed via Cell Counting Kit-8 (CCK-8) assay, while clonogenic potential was evaluated through colony formation assay. Apoptotic rates were analyzed by flow cytometry, and cell migratory and invasive capacities were assessed using wound healing and Transwell assays, respectively. The expression of c-Jun and VEGF at both mRNA and protein levels was analyzed through quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting. Furthermore, a xenograft mouse model was established to evaluate the Results: Kae exerted a pronounced inhibitory effect on NPC cell proliferation in a time- and dose-dependent manner. In addition, Kae notably induced apoptosis and markedly suppressed the migration and invasion of C666-1 cells. Mechanistically, Kae treatment led to a dose-dependent downregulation of c-Jun and VEGF expression at both transcript and protein levels. Moreover, silencing c-Jun partially reversed the Kae-induced growth inhibition, apoptosis, and suppression of migration and invasion. Consistently, Conclusions: Kae effectively attenuates NPC cell proliferation, induces apoptosis, and reduces migration and invasion via suppression of the c-Jun/VEGF signaling axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.